BiotechTube

APR-246 + Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD)

Phase 1/2Completed
0 views this week 0 watching💤 Quiet
Interest: 22/100
22
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53

Conditions

Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53

Trial Timeline

Mar 1, 2014 → Apr 1, 2019

NCT ID
NCT02098343

About APR-246 + Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD)

APR-246 + Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD) is a phase 1/2 stage product being developed by Aprea Therapeutics for Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53. The current trial status is completed. This product is registered under clinical trial identifier NCT02098343. Target conditions include Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53.

What happened to similar drugs?

0 of 7 similar drugs in Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53 were approved

Approved (0) Terminated (2) Active (5)
❌OLAPARIB + PLACEBOAstraZenecaPhase 3
🔄OLAPARIB + Single agent chemotherapyAstraZenecaPhase 3
🔄Olaparib 300mg tablets + Placebo to match olaparib 300mgAstraZenecaPhase 3
❌Nemvaleukin and Pembrolizumab Combination + Pembrolizumab + Nemvaleukin + Pegylated Liposomal Doxorubicin (PLD) + Paclitaxel + Topotecan + GemcitabineMerckPhase 3
🔄Rina-S + Paclitaxel + Topotecan + Pegylated liposomal doxorubicin (PLD) + GemcitabineGenmabPhase 3
🔄ZL-2306(nirapairb) + PlacebosZai LabPhase 3
🔄olvimulogene nanivacirepvec + Platinum chemotherapy: carboplatin (preferred) or cisplatin + Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin + Bevacizumab (or biosimilar)GeneluxPhase 3

Hype Score Breakdown

Clinical
9
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02098343Phase 1/2Completed

Competing Products

20 competing products in Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53

See all competitors
ProductCompanyStageHype Score
PRGN-3005 UltraCAR-T cells + PRGN-3005 UltraCAR-T cellsPrecigenPhase 1
27
OSI-906 + erlotinib + placeboAstellas PharmaPhase 2
35
ASP1650Astellas PharmaPhase 2
35
Niraparib + AnlotinibSun PharmaceuticalPhase 2
35
E7050 + CetuximabEisaiPhase 1/2
32
Farletuzumab + PlaceboEisaiPhase 2
35
PLD 40mg/m2 ivgtt q4w +Apatinib 250mg po qd + PLD 40mg/m2 ivgtt q4wJiangsu Hengrui MedicinePhase 2
31
OLAPARIBAstraZenecaPhase 2
35
Batiraxcept + DurvalumabAstraZenecaPhase 1/2
24
cediranib and olaparibAstraZenecaPhase 2
35
Durvalumab and Tremelimumab + AZD1775 and carboplatin (CBPT) + AZD6738 and olaparibAstraZenecaPhase 2
35
olaparib+cediranib combination therapy + durvalumab + olaparib combination therapy + durvalumab + chemotherapy treatment + durvalumab + tremelimumab + chemotherapy treatment + durvalumab + tremelimumab + paclitaxel treatment + durvalumab +chemotherapy treatmentAstraZenecaPhase 2
31
OLAPARIB + PLACEBOAstraZenecaPhase 3
32
ZD4054 Zibotentan + Paclitaxel + Carboplatin + PlaceboAstraZenecaPhase 2
27
OLAPARIB + Single agent chemotherapyAstraZenecaPhase 3
40
Olaparib 300mg tablets + Placebo to match olaparib 300mgAstraZenecaPhase 3
44
TILT-123 + pembrolizumab + pegylated liposomal doxorubicinMerckPhase 1/2
39
OSE2101 + Pembrolizumab 25 MG/ML [Keytruda]MerckPhase 2
39
Nemvaleukin and Pembrolizumab Combination + Pembrolizumab + Nemvaleukin + Pegylated Liposomal Doxorubicin (PLD) + Paclitaxel + Topotecan + GemcitabineMerckPhase 3
32
IBI363+IBI305Innovent BiologicsPhase 2
42